Proposal to widen hospital funding restrictions for rituximab

Medicines

Consultation Closed

PHARMAC is seeking feedback on a proposal to amend the funding restrictions for rituximab in hospitals to include the following indications:

  • Cold haemagglutinin disease;
  • Warm autoimmune haemolytic anaemia;
  • Immune thrombocytopenic purpura;
  • Thrombotic thrombocytopenic purpura;
  • Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis;
  • Systemic lupus erythematosus;
  • Antibody-mediated renal transplant rejection; and
  • ABO-incompatible renal transplant.

We do not have a proposed implementation date because it would be dependent on the consultation responses received. We may have to seek further clinical advice following consultation. We will notify all relevant parties when a decision is made on any aspect of this proposal.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Monday, 30 September 2013 to:

Sue Anne Yee
Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143

Email: sueanne.yee@pharmac.govt.nz

Fax:     04 460 4995

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.